The immune system is a complex network of cells, tissues, and organs that serves as the body’s first line of defence against infections, viruses, and diseases like cancer. In order to maintain immune homeostasis and prevent autoimmune diseases, immunological checkpoints are essential immune regulators. Immune checkpoints are inhibitory immune system controllers that are crucial for maintaining self-tolerance, preventing autoimmune disorders, and controlling the strength and duration of immune responses to minimize collateral tissue damage. Because these, immunological checkpoints are often overexpressed on tumour cells or on non-transformed cells in the tumour microenvironment, they prevent the immune system from successfully mounting an anti-tumor response. Immune responses are regulated by a balance between co-stimulatory and inhibitory signalling pathways, which are activated by a variety of receptors and the ligands that bind to them. Due to this, a variety of checkpoint inhibitor antibody medicines have been created and are presently undergoing clinical trials or have already received approval for the treatment of various malignancies.
Abeomics offers a wide selection of immunological check point products, including PD-1, CD25, PD-L1, CD70, B7-H4, and PD-L2, which help researchers and scientists carry out their work in an efficient and effective way.
